Seroepidemiology of HBV/HCV in Pakistan

被引：19
|
作者：
Zuberi, SJ
机构：
来源：
INTERNATIONAL HEPATOLOGY COMMUNICATIONS | 1996年 / 5卷 / 01期
关键词：
hepatitis B; hepatitis C; chronic liver disease; hepatocellular carcinoma; vaccination;
D O I：
10.1016/S0928-4346(96)82006-8
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Pakistan is an endemic country for all types of human hepatitis viruses. Their geographical prevalence depends on the ethnicity of population in various areas and their cultural and religious practices. Major etiological factors are faulty injection/transfusion practices, quackery and bad hygienic habits. This paper presents cumulative data of HBV/HCV in various groups. Viral markers in all studies were done using EIA technique.
引用
收藏
页码：19 / 26
页数：8
相关论文
共 50 条
  • [31] HCV core antigen testing in HIV- and HBV-coinfected patients, and in HCV-infected patients on hemodialysis
    Mederacke, Ingmar
    Potthoff, Andrej
    Meyer-Olson, Dirk
    Meier, Matthias
    Raupach, Regina
    Manns, Michael P.
    Wedemeyer, Heiner
    Tillmann, Hans Ludger
    JOURNAL OF CLINICAL VIROLOGY, 2012, 53 (02) : 110 - 115
  • [32] HIV, HCV and HBV: A Review of Parallels and Differences
    Maria C. Leoni
    Andrew Ustianowski
    Hamzah Farooq
    Joop E. Arends
    Infectious Diseases and Therapy, 2018, 7 : 407 - 419
  • [33] Editorial: Recent advances in HBV and HCV immunology
    Dustin, Lynn B.
    Trehanpati, Nirupma
    FRONTIERS IN IMMUNOLOGY, 2015, 6
  • [34] HIV, HCV and HBV: A Review of Parallels and Differences
    Leoni, Maria C.
    Ustianowski, Andrew
    Farooq, Hamzah
    Arends, Joop E.
    INFECTIOUS DISEASES AND THERAPY, 2018, 7 (04) : 407 - 419
  • [35] Safety and efficacy of immune checkpoint inhibitors in patients with HBV/HCV infection and advanced-stage cancer: A systematic review
    Pu, Dan
    Yin, Liyuan
    Zhou, Yuwen
    Li, Wen
    Huang, Lin
    Cai, Liang
    Zhou, Qinghua
    MEDICINE, 2020, 99 (05) : E19013
  • [36] Trends in the total numbers of HBV and HCV carriers in Japan from 2000 to 2011
    Tanaka, J.
    Akita, T.
    Ohisa, M.
    Sakamune, K.
    Ko, K.
    Uchida, S.
    Satake, M.
    JOURNAL OF VIRAL HEPATITIS, 2018, 25 (04) : 363 - 372
  • [37] Clinical prediction of HBV and HCV related hepatic fibrosis using machine learning
    Wei, Runmin
    Wang, Jingye
    Wang, Xiaoning
    Xie, Guoxiang
    Wang, Yixing
    Zhang, Hua
    Peng, Cheng-Yuan
    Rajani, Cynthia
    Kwee, Sandi
    Liu, Ping
    Jia, Wei
    EBIOMEDICINE, 2018, 35 : 124 - 132
  • [38] Interferon: A Sharp Sword to Overcome HCV or HBV-Related Liver Diseases?
    Jia, Wei-Dong
    Zhang, Chuan-Hai
    HEPATITIS MONTHLY, 2010, 10 (03) : 237 - 238
  • [39] Sorafenib in the Treatment of Virus-Related HCC: Differences Between HCV and HBV
    De Matteis, Serena
    Ghetti, Martina
    Gramantieri, Laura
    Marisi, Giorgia
    Casadei-Gardini, Andrea
    ONCOTARGETS AND THERAPY, 2021, 14 : 4305 - 4308
  • [40] Evaluation of alternative serum biomarkers to monitor the progression of chronic HBV and HCV infection
    Tsiomita, S.
    Georgopoulou, U.
    Doumba, P. P.
    Koskinas, J.
    Adamidis, K.
    Papaloukas, C.
    Thyphronitis, G.
    INFECTION GENETICS AND EVOLUTION, 2018, 58 : 17 - 22
12345